The $ 38 billion US commercial weight loss market is 15% higher than in 2020, but it had to turn to adapt to the huge competition of popular GLP-1 drugs.
$38.4 Billion U.S. Commercial Weight Loss Market Pivots to Survive GLP-1 Drugs Explosion
Drugs
$33.8 Billion U.S. Medical Weight Loss Market Now Dominated by GLP-1 Drugs
At one time, the history of the United States weight loss market has been dominated by a single product such as new GLP-1 weight loss drugs. US diets have come to them, avoiding commercial weight loss programs such as weight monitoring, mediifast, and retail and MLM meals.
4 Blockbuster Drugs to Watch for Non-Small Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC) accounts for 80–85% of all lung cancer diagnoses and poses challenges in early detection due to symptoms often resembling common illnesses or long-term smoking effects.